I have expertise and an established track record in the area of breast cancer, stretching from the laboratory to the clinical, with special expertise in the areas of antiangiogenic drug development and breast cancer murine models of growth and metastasis, as well as expertise in the area of breast cancer genomics. I have extensive experience with athymic (nude) mouse models of metastasis, and have published extensively in this area for a variety of established and novel agents. I have devoted much of the past 2 decades in the clinic to the development of novel biologic agents for breast cancer. My clinical drug development experience has spanned Phase I, II and III clinical trials, predominantly in breast cancer. In addition, at a national level I have served on numerous study sections, ad hoc site visit groups, and research panels, including service on the DOD Breast Cancer Research Program’s Integration Panel. I have also served as a member of the FDA’s ODAC committee and as chair of the ECOG Breast Cancer Committee, as well as currently serving as co-program leader for the Indiana University Simon Cancer Center’s Breast Cancer Program. I am currently President-Elect of the American Society of Clinical Oncology. Recently I have co-authored working involving host variation and outcome in breast cancer (see below under references) relevant to this proposal. This wide range of experience in lab, clinic, and higher-level drug development and regulatory issues qualifies me to provide mentorship within the area of breast cancer as outlined in this proposal.